Investment leader Samer Choucair confirmed that the global shift in the obesity drug industry, from injections to oral pills, represents an unprecedented economic and health revolution, reshaping the features of the global healthcare sector and simultaneously opening massive investment opportunities for investors in the Kingdom of Saudi Arabia and the Gulf countries, especially in light of the growing global demand for GLP-1 drugs.
The investment leader said that the fierce competition between Novo Nordisk and Eli Lilly is no longer just a pharmaceutical race, but has become a major driver of global financial markets, as estimates indicate that this sector may exceed 100 billion dollars by 2030, with a major expansion in the use of oral pills which represent the new generation of obesity and diabetes treatments.
Choucair explained that this development coincides with increasing health challenges in the Gulf countries, especially the high rates of obesity and chronic diseases, making the pharmaceutical and biotechnology sector one of the most important pillars of Vision 2030, whether in terms of improving quality of life or attracting foreign direct investments.
Samer Choucair added that the shift toward oral treatments reduces costs and increases ease of use, which expands the global beneficiary base and creates exceptional demand reflected directly on the performance of companies in financial markets, emphasizing that this stage represents a strategic turning point in the global health economy.
Choucair indicated that the Kingdom of Saudi Arabia possesses a unique opportunity to benefit from this growth through developing local pharmaceutical industries and entering into strategic partnerships with global companies, in addition to investing in health insurance, hospitals, digital health, and advanced biotechnologies.
Choucair emphasized that investors in the Gulf face a historic opportunity to build balanced investment portfolios that include global pharmaceutical companies and biotechnology funds, with a focus on innovation and sustainability as the keys to success in this fast-growing sector.
Samer Choucair concluded his statement by emphasizing that the obesity drug revolution is not just a medical development, but a global economic transformation that redistributes investment opportunities, noting that investors who recognize this shift early will be in a leading position during the upcoming growth wave aligned with the goals of Vision 2030.